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Abstract
Objective—We evaluated whether improvements in pregnancy outcomes after treatment of mild
GDM differed in magnitude based on fetal gender.
Methods—This is a secondary analysis of a masked RCT of treatment for mild GDM. Outcomes
included preeclampsia or gestational hypertension, birth weight, neonatal fat mass, and composite
adverse outcomes for both neonate (preterm birth, SGA or NICU admission) and mother (labor
induction, cesarean delivery, preeclampsia or gestational hypertension). After stratification
according to fetal gender, the interaction of gender with treatment status was estimated for these
outcomes.
Results—Of 469 pregnancies with male fetuses, 244 were randomized to treatment and 225 to
routine care. For those with female fetuses, these numbers were 463, 233 and 230 respectively.
The interaction of gender with treatment status was significant for fat mass (p=0.04) and
birthweight centile (p = 0.02). Among women who were assigned to the treatment group, male
offspring were significantly more likely to have both a lower birth weight centile (50.7 ± 29.2 vs
62.5 ± 30.2 centile, p < 0.0001) and less neonatal fat mass (487 ± 229.6 vs. 416.6 ± 172.8 g, p =
0.0005) whereas these differences were not significant among female offspring. There was no
interaction between fetal gender and treatment group with regard to other outcomes.
Conclusion—The magnitude of the reduction of a newborn’s birth weight centile and neonatal
fat mass related to the treatment of mild GDM appears greater for male neonates.
Keywords
gender; gestational diabetes mellitus; pregnancy outcomes
Introduction
Two recent randomized studies reported that therapy of mild gestational diabetes mellitus
(GDM) results in a reduction of birth weight.1,2 In one of these studies, performed by the
NICHD Maternal Fetal Medicine Unit (MFMU) Network, 2 we also reported a significant
reduction in neonatal fat mass in the treatment versus the standard clinical care group.
GDM is characterized by increased oxidative stress (OS) in both maternal blood and
placental tissues.3 Recent laboratory studies of hepatic cells in culture demonstrated that
H2O2 increased the production of SREBP1c (sterol regulatory element-binding protein-1c),
a transcription factor which controls the expression of fatty acid and cholesterol biosynthesis
genes.4 H2O2 treatment resulted in increased lipid accumulation in these cells. Interesting
reports have surfaced suggesting that vascular tissues from male animals generate more OS 5
and also that cells from males are more susceptible to OS.6 In humans, treatment of
disorders in which increased OS is a pathologic feature reportedly results in a greater
therapeutic response in males.7
Given that lipogenesis has been associated with increased oxidative stress4, and that males
appear to be more sensitive to the insults of oxidative stress5,6, we hypothesized that fetal
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gender could affect outcomes related to the treatment of GDM. Thus, we sought to
determine whether treatment of mild GDM differentially affected maternal and perinatal
outcomes based on the fetal gender.
Materials and Methods
This is a secondary analysis of data collected during a randomized trial of treatment for mild
GDM2 at 10 participating centers in the Eunice Kennedy Shriver National Institute of Child
Health and Human Development Maternal-Fetal Medicine Units Network between October
2002 and November 2007. Institutional research board approval was obtained from each of
the participating centers for the conduct of the primary study.
The details of study design, outcomes, and statistical analyses were previously published in
the principal analysis of these data2. In brief, women who were between 24 and 30 weeks
and 6 days at the time of 50 g glucose challenge test, and whose 1-hour blood glucose value
was between 135 and 200 mg per deciliter (7.5 to 11.1 mmol per liter), underwent a 3-hour
oral glucose tolerance test (OGTT). Mild GDM was defined, on the basis of this OGTT,
using criteria proposed by the Workshop of the Fourth International conference of
Gestational Diabetes Mellitus8, namely fasting blood sugar < 95 mg per deciliter (5.3 mmol
per liter) and two or more elevated post challenge thresholds: 1-hour, >180 mg per deciliter
(10.0 mmol per liter); 2-hour, >155 mg per deciliter (8.6 mmol per liter), and 3-hour, > 140
mg per deciliter (7.8 mmol per liter). Exclusion criteria were: preexisting diabetes mellitus,
history of stillbirth, multi-fetal pregnancy, asthma or chronic hypertension, current use of
corticosteroids, known fetal anomaly, or anticipated imminent preterm delivery. Those who
had no exclusion criteria, who had mild GDM, and who consented to participation were then
randomly assigned by the coordinating center to nutritional counseling and diet9 with insulin
use as needed (treatment group) or to routine prenatal care (control group). An additional
group of women, who had a normal OGTT were also enrolled by the coordinating center
into the group of women who received routine prenatal care in order to ensure that medical
personnel would be unaware whether patients in the group had mild GDM. Insulin therapy
was initiated if the majority of fasting or postprandial values were elevated (fasting ≥ 95 mg
per deciliter or 2-hour postprandial ≥ 120 mg per deciliter [6.7 mmol per liter]). Random
values > 160 mg per deciliter (8.9 mmol/liter) or fasting values ≥ 95 mg/dL were used as
criteria for initiating insulin in the control group. Such patients were not removed from the
control group as the analysis was conducted according to the intention to treat principle.
Maternal outcomes that were assessed included hypertensive disease of pregnancy, shoulder
dystocia, and cesarean delivery. Neonatal outcomes included hypoglycemia,
hyperinsulinemia,10 hyperbilirubinemia, elevated cord-blood C-peptide levels, birth weight,
fat mass, stillbirth or neonatal death, and birth trauma. For this secondary analysis, the
outcomes were evaluated using not only raw birth weight but also centiles and z-scores
based on published standard populations.11 Additionally, the effect of therapy on lean body
mass, defined as birth weight minus fat mass, of the neonate was determined. Composite
adverse outcomes for both the neonate (preterm birth, SGA or NICU admission) and the
mother (labor induction, cesarean delivery, preeclampsia or gestational hypertension) were
evaluated. Hyperinsulinemia was defined as cord blood C-peptide level > 95th percentile
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(1.77 ng per milliliter), while hypoglycemia was defined as glucose < 35 mg/deciliter (1.9
mmol per liter).10 Neonatal fat mass was estimated based on the technique described by
Catalano et al, which 12 combines measurement of chest and limb circumferences with
caliper measurement of skinfold thickness to estimate subcutaneous fat mass.
The focus of this secondary analysis was whether there was an interaction between fetal
gender and treatment group with regard to obstetric and perinatal outcomes. Thus, the
frequencies of outcomes based on treatment status (i.e., treatment versus routine care) were
stratified according to a newborn’s gender. For categorical variables, the Breslow-Day test
for homogeneity of the odds ratios was used to test for the presence of interactions. For
continuous variables, Student’s t-test was used for univariate analysis and analysis of
variance (ANOVA) was used to test for the presence of interactions. Lastly, because the
study groups were not balanced with regard to alcohol use,2 which was more prevalent in
the treatment group, regression models were generated that estimated the interactions
between fetal gender and outcome while controlling for the potentially confounding variable
of alcohol use.
Statistical analyses were conducted with SAS software (SAS Institute, Cary, NC). A
nominal two-sided P value less than 0.05 was considered to indicate statistical significance
and no adjustments were made for multiple comparisons.
Results
There were a total of 469 women with male fetuses and 463 women with female fetuses in
the study population who met inclusion criteria for this analysis and had delivery data
available. As noted in the primary analysis2 there was no significant difference in maternal
BMI on entry into the study. There were no significant interactions between fetal gender and
treatment group with regard to the majority of perinatal (Table 1) or maternal (Table 2)
outcomes. There were, however, significant interactions between treatment group and
gender for birth weight centile (p=0.02), as well as for neonatal fat mass (p=0.04) (Table 1).
Specifically, male offspring were significantly more likely to have both a lower birth weight
centile (50.7 ± 29.2 v 62.5 ± 30.2 centile, p < 0.0001) and less neonatal fat mass (487 ±
229.5 vs. 416.6 ± 172.8 g, p = 0.0005) whereas these differences were not significant among
female offspring. Conversely, there was no significant difference in lean body mass (Table
1) which may indicate that the weight difference observed with treatment was due to the
effect on fat accretion. Results were similar after adjustment for alcohol use.
There was no significant interaction between gender and treatment in the development of
macrocosmic (BW > 4000g). The frequency of this outcome in treated and untreated male
pregnancies were 18/244 (7.4%) and females 10/233 (4.3%) and 24/230 (10.4%)
respectively, P=0.87 (Breslow Day Test for homogeneity of the odds ratio).
Inclusion of maternal BMI did not significantly affect the role of fetal gender in the newborn
outcomes.
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The results of this secondary analysis from the NICHD MFMU Network suggest that there
may be an interaction between fetal gender and treatment of mild GDM such that there is a
significantly greater reduction, associated with treatment, in both birth weight and
accumulated fat mass in males than in females. There was however no interaction with
regard to lean body mass.
The cause of this apparent differential effect of treatment of women with mild GDM is not
known with certainty. It is intriguing to consider whether these observations could be
explained by gender differences in susceptibility to oxidative stress (OS) or in the response
to interventions that mitigate OS. Markers of OS have been shown to be present in maternal,
placental and newborn tissues from women with GDM,3 and OS is known to have an
important role in lipogenesis and fat accumulation 3,13. Moreover, there is evidence that
males both are more susceptible to OS 5,6 and more likely to benefit from treatment aimed at
reducing OS7. Based on these reports, we hypothesized that there would be a differential
response, based on fetal gender, to treatment of mild GDM, a disorder characterized by
OS 3. Indeed, just such a differential response was seen with regard to birth weight and fat
accretion. In contrast, we found no other significant interaction between gender and
treatment with regard to other perinatal or maternal outcomes.
The finding of an apparent differential benefit for male fetuses from maternal treatment of
mild GDM is interesting. Because the reduction in birth weight was noted to be due to a
reduction in fat mass and not lean body mass, this difference may have additional
ramifications, as neonatal fat mass has been linked to long-term health problems including
impaired glucose tolerance and childhood obesity.13, 14
A limitation of the study is that this was an unplanned secondary analysis. As such, we were
unable to directly measure markers of OS in maternal, placental and newborn tissues.
Another potential limitation is the possibility of a type I error given the number of
comparisons made. Despite these limitations, our findings are intriguing and potentially
consequential. In an age of increasing interest in personalized medicine, the important
differential effects of therapy and prognosis based on gender have received little attention
overall and even less in perinatal medicine. The current report suggests a need for further
investigation concerning the relationship of gender to neonatal and pediatric outcomes in
diabetic pregnancies.
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N. Fredericks, E. Gantioqui, B. Greenspan, M. Williams
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University of Utah — K. Anderson, P. Ashby, S. McAllister (University of Utah Health
Sciences Center); S. Quinn, F. Castinella (LDS Hospital), A. Guzman ; J. Steiner (McKay-
Dee Hospital), J. Parker (Utah Valley Regional Medical Center)
University of Alabama at Birmingham — J. Sheppard, J. Tisdale, A. Northen, W. Andrews
Brown University — D. Catlow, D. Allard, M. Seebeck, J. Tillinghast
The Ohio State University — J. Iams, F. Johnson, C. Latimer, E. Weinandy, B. Maselli
University of North Carolina at Chapel Hill — K. Dorman, S. Brody, S. Timlin, J.
Bernhardt
Drexel University — M. Hoffman, E. Guzman, M. Talucci, T. Grossman, C. Perez, L.
Zeghibe, P. Tabangin
Case Western Reserve University-MetroHealth Medical Center — B. Mercer, B. Stetzer, C.
Milluzzi, W. Dalton, S. Pichette
Wake Forest University Health Sciences — M. Swain, P. Meis, J. White
The University of Texas Health Science Center at Houston — L. Gilstrap, K. Cannon, J.
Martinez, D. Dusek
University of Texas Medical Branch — J. Moss, J. Brandon, A. Jackson, G. Hankins, D.
Sharp
University of Pittsburgh — M. Bickus, H. Birkland, M. Cotroneo, N. Cuddy
Northwestern University — P. Simon, G. Mallett
Oregon Health & Science University — L. Davis, E. Lairson, C. Cromett, C. Naze, M.
Blaser
The George Washington University Biostatistics Center — E.Thom, J. Zachary, B.
Getachew, C. Cobb, L. Leuchtenburg, S. Gilbert
Eunice Kennedy Shriver National Institute of Child Health and Human Development — C.
Spong, S. Tolivaisa, K. Howell
MFMU Network Steering Committee Chair (University of Texas Medical Branch,
Galveston, TX) — G.D. Anderson, M.D.
Condensation:
The beneficial effects of treatment of mild gestational diabetes in reducing birth weight and
neonatal fat mass is greater in magnitude among male fetuses.
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